CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Stereotactic Body Radiation Therapyradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01360606
NCT01360606N/ACompleted
CompareCT.gov

A Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases

Susannah Ellsworth·interventional·Posted May 25, 2011·Updated Oct 10, 2024

In Brief

A clinical study evaluating Stereotactic Body Radiation Therapy for Liver Metastases. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This is a phase I dose escalation study. Dose escalation will be via the traditional "up and down" scheme. SBRT: Patients will receive one of the following radiation regimens: * 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period. * 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period. * 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Metastases
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 25, 2011
Enrollment StartMar 23, 2012
Primary CompletionJul 25, 2018
Study CompletionFeb 4, 2021
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 15.1 years ago

Interventions

Stereotactic Body Radiation Therapyradiation

SBRT: Patients will receive one of the following radiation regimens: * 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period. * 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period. * 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.